William A. Hagstrom Sells 30,000 Shares of CareDx, Inc (NASDAQ:CDNA) Stock

CareDx, Inc (NASDAQ:CDNA - Get Free Report) Director William A. Hagstrom sold 30,000 shares of CareDx stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $17.45, for a total value of $523,500.00. Following the transaction, the director now owns 53,979 shares of the company's stock, valued at approximately $941,933.55. This represents a 35.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

CareDx Trading Up 2.1%

CDNA traded up $0.36 during trading on Tuesday, hitting $17.44. The company's stock had a trading volume of 846,057 shares, compared to its average volume of 901,093. The business's fifty day simple moving average is $17.23 and its 200 day simple moving average is $20.46. The firm has a market capitalization of $971.08 million, a price-to-earnings ratio of -6.46 and a beta of 2.27. CareDx, Inc has a twelve month low of $13.18 and a twelve month high of $34.84.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.03. The firm had revenue of $84.69 million for the quarter, compared to analyst estimates of $84.56 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The business's revenue was up 17.6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.03) earnings per share. As a group, equities research analysts forecast that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CDNA. HC Wainwright reiterated a "neutral" rating and set a $25.00 price target on shares of CareDx in a research report on Monday, May 5th. The Goldman Sachs Group reduced their price target on CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. Stephens reiterated an "overweight" rating and set a $40.00 price target on shares of CareDx in a research report on Monday, May 5th. Finally, Wall Street Zen lowered CareDx from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, CareDx has an average rating of "Moderate Buy" and an average price target of $30.33.

Institutional Trading of CareDx

Institutional investors have recently made changes to their positions in the company. Sterling Capital Management LLC boosted its stake in shares of CareDx by 771.2% in the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock worth $27,000 after acquiring an additional 1,126 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of CareDx by 553.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock worth $84,000 after acquiring an additional 3,322 shares during the last quarter. State of Wyoming acquired a new stake in shares of CareDx in the fourth quarter worth approximately $91,000. PNC Financial Services Group Inc. boosted its stake in CareDx by 20,200.0% during the first quarter. PNC Financial Services Group Inc. now owns 4,466 shares of the company's stock worth $79,000 after buying an additional 4,444 shares during the last quarter. Finally, Plato Investment Management Ltd boosted its stake in CareDx by 34.1% during the fourth quarter. Plato Investment Management Ltd now owns 5,390 shares of the company's stock worth $116,000 after buying an additional 1,370 shares during the last quarter.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.